The effect of voglibose on metabolic profiles in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of clinical trials

The effect of voglibose on metabolic profiles in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of clinical trials


چاپ صفحه
پژوهان
صفحه نخست سامانه
چکیده مقاله
چکیده مقاله
نویسندگان
نویسندگان
دانلود مقاله
دانلود مقاله
دانشگاه علوم پزشکی تبریز
دانشگاه علوم پزشکی تبریز

نویسندگان: سعید صفیری

کلمات کلیدی: Voglibose Diabetes mellitus Metabolic profiles Meta-analysis

نشریه: 27198 , 10 , 159 , 2020

اطلاعات کلی مقاله
hide/show

نویسنده ثبت کننده مقاله سعید صفیری
مرحله جاری مقاله تایید نهایی
دانشکده/مرکز مربوطه عوامل اجتماعی موثر بر سلامت
کد مقاله 72654
عنوان فارسی مقاله The effect of voglibose on metabolic profiles in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of clinical trials
عنوان لاتین مقاله The effect of voglibose on metabolic profiles in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of clinical trials
ناشر 13
آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ خیر
عنوان نشریه (خارج از لیست فوق)
نوع مقاله Systematic Review Article
نحوه ایندکس شدن مقاله ایندکس شده سطح یک – ISI - Web of Science
آدرس لینک مقاله/ همایش در شبکه اینترنت

خلاصه مقاله
hide/show

Objective The effect of voglibose on metabolic homeostasis is not well characterized. Therefore, we conducted a systematic review and meta-analysis of clinical trials assessing the effect of voglibose on metabolic profile in patients with type 2 diabetes mellitus (T2DM). Methods Systematic searches were conducted in PubMed, Scopus, Embase, Google Scholar, Web of Science and Cochrane Library to identify clinical trials assessing the effects of voglibose supplementation on cardio-metabolic profile from incept up to 29 July 2019. Data was pooled using fixed- or random-effect models and weighted mean difference (WMD) as the effect size. Results Eight clinical trials from 1094 reports, were eligible for inclusion. Pooled findings identified significant reductions in hemoglobin A1c (HbA1c) (WMD= −0.27; 95 %CI −0.49 to −0.05; P = 0.01; I2 = 64.8 %) and an increase in LDL-cholesterol levels (WMD=5.97 mg/dl, 95 % CI 0.88, 11.06, P = 0.02; I2 = 0.0 %). However, no evidence of effect for voglibose intake on T2DM patients was observed for: fasting blood sugar (FBS) (WMD −7.43 mg/dl; 95 %CI -16.56 to 1.71; P = 0.110; I2 = 69.3 %), serum insulin (WMD= −0.15 μU/mL; 95 %CI −0.89 to 0.60; P = 0.70; I2 = 0.0 %), total-cholesterol (WMD=2.82 mg/dl, 95 %CI -2.36 to 8.01, P = 0.70; I2 = 49.7 %), triglycerides (WMD= −7.07 mg/dl, 95 %CI −21.76 to 7.62, P = 0.34; I2 = 0.0 %), HDL-cholesterol levels (WMD= −2.10 mg/dl, 95 %CI −4.48 to 0.27, P = 0.08; I2 = 0.0 %,), body mass index (BMI) (WMD=0.09 kg/m2, 95 %CI −0.70 to 0.87; P = 0.87; I2 = 0.0 %), body weight (WMD= −0.42 kg, 95 %CI −0.84 to 0.00; P = 0.05; I2 = 0.0 %), and adiponectin levels (WMD = 0.32 μg/mL, 95 %CI −0.74 to 1.38; P = 0.55; I2 = 0.0 %). Conclusions The current meta-analysis identified a decrease in HbA1c and an increase in LDL-cholesterol with administration of voglibose. However, no significant effect was observed on FBS, insulin, bodyweight, BMI, adiponectin, triglycerides, total- and HDL-cholesterol levels.

نویسندگان
hide/show

نویسنده نفر چندم مقاله
سعید صفیریسیزدهم

لینک دانلود مقاله
hide/show

نام فایل تاریخ درج فایل اندازه فایل دانلود
Phramacological Research.pdf1399/04/021450068دانلود
Pharmacological Research ScienceDirect.JPG1399/04/02100379دانلود